尖峰集团：子公司获得化学原料药上市申请批准通知书

Core Viewpoint - The announcement indicates that Jianfeng Group's subsidiary, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Fosfomycin Trometamol, which is a new antibacterial medication developed by Cubist Pharmaceuticals [1] Company Summary - Jianfeng Group's subsidiary has established production lines capable of manufacturing Fosfomycin Trometamol, indicating readiness to enter the market [1] - The approval signifies that the raw material drug meets the national technical standards for raw material drug review, allowing it to be sold in the domestic market [1] - This development is expected to help expand the business scope of the subsidiary [1]